Sight Sciences, Inc. (SGHT)

In the past six months, Sight Sciences reported Q2 2025 financial results with a revenue decrease due to lower Surgical Glaucoma segment revenue, but raised its full-year revenue guidance. Lake Street upgraded the stock to "Buy" with a price target increase. The company announced a 20% workforce reduction to cut costs. A meta-analysis demonstrating the OMNI Surgical System's benefits was published. A fee schedule was established for the TearCare procedure. The company announced the date for its Q3 2025 earnings announcement. The stock experienced a significant gain in the month leading up to October 18, 2025.

Demand for Sight Sciences' products may exhibit some seasonality, particularly for dry eye disease treatments, with symptoms increasing in the fall and winter and potentially exacerbated by environmental allergens in the spring. Glaucoma interventions may also be influenced by seasonal variations in intraocular pressure, which is generally highest in winter and lowest in summer. The overall market is driven by factors like the rising prevalence of eye diseases, an aging population, and technological advancements.

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing surgical and non-surgical technologies for treating eye diseases like glaucoma and dry eye disease. Their product portfolio includes the OMNI Surgical System and SION Surgical Instrument for glaucoma, and the TearCare System for dry eye. The company was founded in 2010 and is headquartered in Menlo Park, California.

Sight Sciences primarily sells its products in the United States through sales representatives and distributors to hospitals, medical centers, and eyecare professionals. The company is also developing a global commercial infrastructure in select international markets, with the OMNI Surgical System holding CE Marking for use in Europe.

Sight Sciences maintains a brand reputation focused on innovation and transforming eye care through interventional technologies. Clinical publications have demonstrated the efficacy and cost-effectiveness of their products. The company continues to introduce new technologies and has received industry recognition for its focus on unmet needs in eye care. A workforce reduction was framed as a strategic effort to reduce costs and improve efficiency.

The ownership of Sight Sciences stock is a mix of institutional, insider, and retail investors. Approximately 55.51% of the stock is held by institutions, with major shareholders including KCK Ltd., Long Focus Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Insiders hold approximately 28.90% of the stock, with Staffan Encrantz being the largest individual shareholder. In the past three months, insiders have sold more company stock than they have bought.